Navigation Links
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Date:10/2/2007

NEW YORK, Oct. 2 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the ERBITUX(R) (Cetuximab) product labeling to include overall survival data as a single agent in epidermal growth factor inhibitor (EGFR)-expressing metastatic colorectal cancer (mCRC) patients after failure of both irinotecan- and oxaliplatin-based regimens.

The approval of the supplemental biologics license application (sBLA) is based on prolonged overall survival from a large, randomized, multicenter, Phase III trial comparing ERBITUX plus best supportive care (BSC) to BSC alone in 572 EGFR-expressing mCRC patients after failure of irinotecan- and oxaliplatin-based regimens. BSC was considered to be all approved palliative therapies designed to alleviate pain and treat other effects caused by mCRC in this patient population.

"We are very pleased that the FDA has recognized these data as the second disease setting where ERBITUX has improved overall survival - which is the ultimate goal of all cancer therapies," said Eric K Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "This approval for ERBITUX as a monotherapy offers an additional treatment option for an expanded patient population, specifically, patients who have failed both irinotecan- and oxaliplatin-based chemotherapy regimens."

"ERBITUX is now t
'/>"/>

SOURCE Bristol-Myers Squibb Company; ImClone Systems Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
9. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
10. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015  Check-Cap Ltd. (NASDAQ: CHEK ), ... development of a preparation-free ingestible imaging capsule that utilizes ... today that its CEO, Guy Neev , will ring ... day.  Neev and Check-Cap will participate in the closing ... public offering and simultaneous private placement which raised a ...
(Date:3/30/2015)... 2015 Perrigo Company plc (NYSE: PRGO ... Healthcare Products®," today announced that it has completed the ... a cash and equity transaction valued at approximately €3.8 ... debt. Sellers are Marc Coucke , Waterland Private ...   "The combination of Perrigo and ...
(Date:3/30/2015)... BOSTON , March 30, 2015  MedAptus® ... newest solution designed to simplify pre-care needs for ... rules-based intelligence to automatically assign patients to hospitalists ... continuity of care and other requirements such as ... efficiency. ...
Breaking Medicine Technology:Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 2Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 2Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 4Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 5MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 2MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 3
... LOVELAND, Colo., May 16, 2012   Heska Corporation (NASDAQ: ... veterinary diagnostic and other specialty veterinary products, today announced it ... Co. Investor Conference on Wednesday, May 23, 2012 at the ... D in Santa Monica, California.  The presentation is scheduled to ...
... SOUTH SAN FRANCISCO, Calif., May 16, 2012  Rigel Pharmaceuticals, ... respiratory franchise by focusing on two innovative, comprehensive treatment ... R343, an inhaled SYK inhibitor, will be entering a ... to moderate asthmatic patients. The other, R256, an inhaled ...
Cached Medicine Technology:Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 2Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 3Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 4
(Date:3/30/2015)... Textile Exchange, a global nonprofit dedicated to ... the latest version of its Responsible Down Standard ... be applied to any waterfowl-based supply chain to help ... product. The goal of the RDS is to recognize ... enable traceability so that products can be labeled accurately ...
(Date:3/30/2015)... “We are pleased to announce three ... May 30 in Los Angeles,” said Mark Wolper, Chair ... nominated from a nationwide call for nominations. , ... Mid-Atlantic, Richard Durden with LightHawk and Stephen Purello of ... award recipients will receive a $15,000 contribution from the ...
(Date:3/30/2015)... 2015 On March 11, 2015, Elle Magazine, ... Fat,” details six new treatment options for dealing with stubborn, ... is a topical product. The other three technologies use devices ... ) or freezing cold ( CoolSculpting ) to kill fat ... available to us to permanently remove unwanted fat," says Dr. ...
(Date:3/30/2015)... 30, 2015 Innovaacom, a leading provider ... today announced it is expanding its services into Asia ... area of the world comes at a time when ... demand for better healthcare. A rapidly growing aging population ... and advances in medicine in Asia. “We are excited ...
(Date:3/30/2015)... 2015 According to a recently published ... repair market will continue to dominate the European soft ... due to increasing numbers of ventral hernias, and the ... “The significantly large market share represented by ventral hernia ... We’re seeing a growing use of expensive biologics,” explains ...
Breaking Medicine News(10 mins):Health News:Responsible Down Standard 2.0 Released 2Health News:Responsible Down Standard 2.0 Released 3Health News:2015 Endeavor Awards Recipients Announced 2Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Innovaacom Expands Services and Medical Education Programs into Asia 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 3
... A new virus, a modified strain, has led to the ... Britain.// Five other pre mature babies are undergoing treatment. ... Norwich University Hospital after they were found to be carriers ... (S aureus). ,Hospital authorities have confirmed that the ...
... that identifies glucose levels. This sensor plays an important role ... increases or decreases the manufacture of glucose inside the human ... fat for the purpose of storage in adipose tissue. This ... it a potential site that can be targeted to treat ...
... in various hospitals in New York are having a nice ... ,The program is called Clown Care and believes in ... Apple Circus at New York-Presbyterian Hospital runs this program. It ... ago and was introduced by Michael Christensen, co-founder of Big ...
... Gym’ is due largely to the socializing that takes place ... not only for keeping fit and losing weight but also ... ,Nick Crossley, a Professor of Social Sciences from the University ... out the aspects motivating them to join health clubs. He ...
... certain stomach drugs may weaken the bones in the long ... new study that advises doctors to consider the risk when// ... of Pennsylvania Medical School studied records from the general practice ... over 50 and some had been taking proton pump inhibitors ...
... heavy investment opportunities for Non-Resident Keralites (NRK), making it ... term. ,Kerala Tourism Department has planned ... – 27 for showcasing the opportunities in the health ... congregation of major hospitals, health insurance companies, policy makers ...
Cached Medicine News:Health News:Glucose Sensor That Controls Glucose Metabolism Identified 2
... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Eliminate the need for makeshift, modified nebulizer ... waste time gathering parts when your patient ... to deliver the utmost in Heliox rescue ... is fast becoming the standard of care ...
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
Medicine Products: